BioStock: Annexin towards completion of phase II study and share issue

After reporting promising efficacy signals in the ongoing phase II study on patients with the eye disease RVO, Annexin Pharmaceuticals now has a stronger position in licensing and partnership discussions. To finance continued activities, the company also plans to conduct a rights issue of approximately SEK 45 million, with parts of both the board and management intending to participate. BioStock reached out to CEO Anders Haegerstrand for a comment. 

Read the interview with CEO Anders Haegerstrand here:

https://www.biostock.se/en/2024/04/annexin-towards-completion-of-phase-ii-study-and-share-issue/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/